Genelabs Aslera May Offer Some Efficacy For Treatment Of Lupus - FDA Cmte.
Executive Summary
Genelabs Aslera may offer some clinical utility for the treatment of patients with mild to moderate systemic lupus erythematosus, FDA Arthritis Advisory Committee members indicated April 19.
You may also be interested in...
Genelabs Requests Meeting With FDA After Aslera "Not-Approvable" Letter
Genelabs plans to meet with FDA to discuss the NDA for its lupus treatment Aslera (prasterone) following receipt of a "not-approvable" letter June 26.
Genelabs Requests Meeting With FDA After Aslera "Not-Approvable" Letter
Genelabs plans to meet with FDA to discuss the NDA for its lupus treatment Aslera (prasterone) following receipt of a "not-approvable" letter June 26.
Aslera Approval May Be Delayed, Watson Says; Sales Projections Adjusted
Watson expects FDA approval for its lupus treatment Aslera may be delayed following an indecisive advisory committee meeting in April, the company told investors during a May 7 conference call.